Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 466 to 480 of 1251 results for public health guidance

  1. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    Awaiting development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]

    Awaiting development Reference number: GID-TA11583 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Obinutuzumab for treating serologically active extra-renal lupus [ID6670]

    In development Reference number: GID-TA11886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    In development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

    Safe staffing guideline
    Published
    15 July 2014
    View recommendations

    Sections for SG1

  6. What lay members do

    to a member of one of our committees who has personal experience of using health or care services. The phrase could also refer to...

  7. What lay members do

    to a member of one of our committees who has personal experience of using health or care services. The phrase could also refer to...

  8. Accessing NHS care and treatment recommended by NICE (ECD4)

    This document contains advice to help you access treatments and care that NICE has recommended

  9. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    Awaiting development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]

    Awaiting development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development